Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.
Ghanshyam Yadav, MD, resident physician, Baylor College of Medicine, discusses the differences between type 1 and type 2 uterine cancer.
Type 1 uterine cancer is associated with a favorable prognosis, says Yadav. Conversely, patients with type 2 cancer have a poor prognosis. Though rare, 50% to 70% of patients who have type 2 disease have extrauterine spread compared with 4% of patients with type 1 disease.
Type 2 cancer accounts for 40% of uterine cancer deaths despite the rarity of the disease, says Yadav.
Uterine cancer also tends to be resistant to chemotherapy. Therefore, there is a lot of work being done to develop novel targeted therapies, says Yadav. Targeting HER2 alterations could be a potential strategy as the target is expressed in a proportion of patients with uterine cancer, Yadav concludes.